BioCentury
ARTICLE | Distillery Therapeutics

Neurology

August 16, 2018 4:11 PM UTC

In vitro and mouse studies identified a brain-penetrating GlyT1 inhibitor that could help treat schizophrenia. Chemical synthesis of 3,4-disubstituted pyrrolidine sulfonamides and in vitro binding assays yielded a compound that bound GlyT1 with a Ki of 2 nM. In a mouse model of schizophrenia, the compound decreased hyperactivity compared with vehicle. In rats, the compound had a brain-to-plasma ratio of 2:1 when administered intraperitoneally. Next steps by AbbVie Inc. could include optimizing and testing the compound in additional animal models of schizophrenia. ...

BCIQ Company Profiles

AbbVie Inc.